Wall Street Zen Downgrades Terns Pharmaceuticals (NASDAQ:TERN) to Sell

Terns Pharmaceuticals (NASDAQ:TERN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities analysts also recently issued reports on TERN. Oppenheimer lifted their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. UBS Group raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. TD Cowen raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 20th. Leerink Partners initiated coverage on shares of Terns Pharmaceuticals in a research note on Monday, February 9th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, BMO Capital Markets boosted their target price on Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $58.11.

Terns Pharmaceuticals Stock Performance

Shares of NASDAQ TERN opened at $48.44 on Friday. Terns Pharmaceuticals has a 52-week low of $1.87 and a 52-week high of $50.00. The business has a fifty day moving average of $39.70 and a two-hundred day moving average of $27.80. The stock has a market cap of $5.03 billion, a PE ratio of -47.03 and a beta of -0.31.

Insider Buying and Selling at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the transaction, the chief executive officer directly owned 138,976 shares in the company, valued at approximately $5,294,985.60. This represents a 33.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the transaction, the insider directly owned 50,365 shares in the company, valued at $1,942,578.05. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 170,409 shares of company stock worth $6,563,769 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several large investors have recently bought and sold shares of TERN. AlphaQuest LLC raised its position in shares of Terns Pharmaceuticals by 9,088,200.0% during the 3rd quarter. AlphaQuest LLC now owns 90,883 shares of the company’s stock valued at $683,000 after acquiring an additional 90,882 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of Terns Pharmaceuticals by 237.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 66,576 shares of the company’s stock worth $500,000 after purchasing an additional 46,831 shares during the last quarter. DLD Asset Management LP acquired a new stake in shares of Terns Pharmaceuticals during the second quarter worth $138,000. Commodore Capital LP acquired a new stake in shares of Terns Pharmaceuticals during the third quarter worth $42,807,000. Finally, Franklin Resources Inc. bought a new stake in Terns Pharmaceuticals in the second quarter valued at about $4,765,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.